- Joint Academic Rheumatology Program, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
- School of Infection and Immunity, University of Glasgow, United Kingdom
Volume 35, March 2024, Supplement 1
Sign in to download the Issue in PDF format.
1870867994
Mediterr J Rheumatol 2024;35(Suppl 1):27-36
Article Links
Selective JAK-Inhibitors in Spondyloarthritis
Abstract
As our research interest and knowledge increases in the field of Spondyloarthritis, new aspects also emerge as regards to their therapeutic approach. JAK inhibitors (JAKi) are a relatively new treatment option, aiming molecules in the JAK-STAT pathway, which has a leading role in the pathophysiology of both Psoriatic Arthritis and Axial Spondyloarthritis. JAKi exhibit different selectivity towards the four different members of the JAK family (namely JAK1, JAK2, JAK3, and TYK2), possibly reflecting different efficacy and safety profile. Although knowledge is more consolidated for rheumatoid arthritis in which JAKi are being used for more than 10 years, data are still accumulating for PsA/SpA. In this review we aim to present and assess current knowledge about the efficacy of JAKi (with a focus on selective JAKi) in the treatment of patients with SpA and evaluate their safety profile as some concerns may arise around this therapeutic option.
Cite this article as: Vassilakis KD, Magiouf K, Siebert S, Fragoulis GE. Selective JAK-Inhibitors in Spondyloarthritis. Mediterr J Rheumatol 2024;35(Suppl 1):27-36.
Article Submitted: 31 Oct 2023; Article Accepted: 16 Nov 2023; Available Online: 30 Mar 2024
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2024 The Author(s).
